Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339343 | 1.00 | SIGMAR1 (0.45) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL4334477 | 1.00 | SIGMAR1 (0.45) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL4331328 | 0.89 | SIGMAR1 (0.43) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL4331336 | 0.89 | SIGMAR1 (0.43) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL4331333 | 0.89 | SIGMAR1 (0.43) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL4318811 | 0.84 | DRD2 (0.42) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL4318814 | 0.84 | DRD2 (0.42) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL4318818 | 0.80 | CYP2D6 (0.46) | ACHESLC6A4SLC6A3 | |
| SCHEMBL4331270 | 0.80 | — | — | |
| SCHEMBL4334399 | 0.80 | SLC6A3 (0.42) | SIGMAR1HTR2ADRD2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | SIGMAR1 247/4885HTR2A 136/4885HTR2C 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.